^
Association details:
| Biomarker: | PD-L2 overexpression |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Gene expression signature after one dose of neoadjuvant pembrolizumab associated with tumor response in head and neck squamous cell carcinoma (HNSCC).
Excerpt:
Higher expression of PD-L1, PD-L2, and INF-γ in pre-treatment samples were associated with tumor response after one dose of Pembrolizumab (Welch’s t-test, p = 0.015, 0.021, 0.006)....Inflamed tumor microenvironment, evidenced by increased INF-γ irrespective of lymphocyte infiltration is associated with pathological response after a single dose of Pembrolizumab in HNSCC.
DOI:
10.1200/JCO.2018.36.15_suppl.6059
Source:
Title:
Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Excerpt:
Exploratory analyses suggest that PD-L2 and IFN-γ signature may be associated with clinical response to pembro and may offer additional strategies to improve prediction of response.
DOI:
10.1200/JCO.2016.34.15_suppl.6010
Trial ID:
